ANGELA DONOVAN: Open Payments
NPI 1750514485 · ROYAL OAK, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,019 in 17 payments from 15 companies in 2025. Trend: 2023 $1,921 · 2024 $2,513 · 2025 $2,019
Food & beverage: $2,019
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $258 |
| Becton, Dickinson and Company | 1 | $154 |
| AstraZeneca Pharmaceuticals LP | 2 | $149 |
| Averitas Pharma Inc. | 1 | $145 |
| Teva Pharmaceuticals USA, Inc. | 1 | $132 |
| Edwards Lifesciences Corporation | 1 | $131 |
| Alexion Pharmaceuticals, Inc. | 1 | $126 |
| Agios Pharmaceuticals, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Novo Nordisk Inc | 1 | $125 |
Products named: HemoSphere, QUTENZA, Kerendia, UZEDY, KONECT RESILIA, PYRUKYND, REXULTI, Adempas.
Industry payments across MI — which companies pay providers there.
